Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
In vivo characterization of muscarinic receptor-deficit schizophrenia in first-episode psychosis
NL-OMON38703Withdrawn
- Sponsor
- Maastricht University
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of biperiden in schizophrenia and Schizophrenia Spectrum Disorders (SSD) (2 arms), sponsored by Maastricht University. Primary endpoints: M1 receptor binding, BOLD activation during cognitive tasks and 1 more. Planned start Apr 2013; status: withdrawn.
02
Drugs
biperiden
03
Conditions
schizophreniaSchizophrenia Spectrum Disorders (SSD)
Beyond the preview
Go deeper on NL-OMON38703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38703.